Fig. 3

Exogenous E2 supplementation in immune-humanized mice bearing HCI-013 tumors. a Experimental timeline. 6–7 weeks old female NSG-SGM3 mice were injected with 20 mg/kg/day busulfan on two consecutive days. Five days later, mice were IV injected with 85,000 hCD34⁺ HSCs and 24 h later implanted with HCI-013 tumor fragments into the MFP. Animals received E2 supplemented drinking water for 3.5 weeks until the end of the experiment (n = 10, HSC donor ID 12241, KIR-matched to HCI-013). Mice were harvested 14 weeks post-humanization. Control tumors were implanted into non-humanized NSG-SGM3 mice (n = 5). On the day of harvest, BM, blood and spleens were isolated, and flow staining and flow cytometry were performed on the same day without fixation. b Flow cytometry analysis of hCD45⁺ cells in BM, blood and spleen of humanized mice are shown as percent of viable cells (n = 7). c Flow cytometry analysis of hCD3⁺, hCD11b⁺, hCD19⁺ and hCD56⁺ cells in BM, blood and spleens of humanized mice are shown as percent of hCD45⁺ cells (n = 7). All data shown as mean ± SEM